Compare Stocks: GNFT, KURA, GERN, and CLYM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLYM Climb Bio	$17.28 +1.5%	$13.35	$1.54 ▼ $18.14	$992.49M	0.08	1.18 million shs	957,409 shs
GERN Geron	$1.52 -1.9%	$1.42	$1.04 ▼ $2.01	$976.56M	0.61	11.41 million shs	4.43 million shs
GNFT GENFIT	$4.85	$4.47	$3.41 ▼ $4.93	$242.62M	1.09	7,393 shs	N/A
KURA Kura Oncology	$11.89 +1.5%	$10.53	$7.36 ▼ $12.90	$1.06B	0.38	1.79 million shs	2.03 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLYM Climb Bio	0.00%	+5.82%	+35.42%	+57.09%	+668.00%
GERN Geron	0.00%	+3.40%	+4.83%	+18.75%	+9.35%
GNFT GENFIT	0.00%	0.00%	0.00%	0.00%	+12.27%
KURA Kura Oncology	0.00%	+9.48%	+13.78%	+5.69%	+68.65%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLYM Climb Bio	$17.28 +1.5%	$13.35	$1.54 ▼ $18.14	$992.49M	0.08	1.18 million shs	957,409 shs
GERN Geron	$1.52 -1.9%	$1.42	$1.04 ▼ $2.01	$976.56M	0.61	11.41 million shs	4.43 million shs
GNFT GENFIT	$4.85	$4.47	$3.41 ▼ $4.93	$242.62M	1.09	7,393 shs	N/A
KURA Kura Oncology	$11.89 +1.5%	$10.53	$7.36 ▼ $12.90	$1.06B	0.38	1.79 million shs	2.03 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLYM Climb Bio	0.00%	+5.82%	+35.42%	+57.09%	+668.00%
GERN Geron	0.00%	+3.40%	+4.83%	+18.75%	+9.35%
GNFT GENFIT	0.00%	0.00%	0.00%	0.00%	+12.27%
KURA Kura Oncology	0.00%	+9.48%	+13.78%	+5.69%	+68.65%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLYM Climb Bio	3.00	Buy	$22.75	31.66% Upside
GERN Geron	2.20	Hold	$4.00	163.16% Upside
GNFT GENFIT	2.00	Hold	$7.00	44.33% Upside
KURA Kura Oncology	2.69	Moderate Buy	$25.62	115.44% Upside

Current Analyst Ratings Breakdown

Latest GNFT, KURA, GERN, and CLYM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2026	CLYM Climb Bio	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$20.00
8/13/2026	KURA Kura Oncology	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$36.00 ➝ $38.00
8/11/2026	GERN Geron	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/7/2026	CLYM Climb Bio	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$17.00 ➝ $25.00
8/3/2026	CLYM Climb Bio	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$23.00
8/3/2026	CLYM Climb Bio	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Moderate Buy	$23.00
7/28/2026	KURA Kura Oncology	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$36.00
7/27/2026	CLYM Climb Bio	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$17.00 ➝ $20.00
7/24/2026	GERN Geron	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/17/2026	CLYM Climb Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	KURA Kura Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 8/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLYM Climb Bio	N/A	N/A	N/A	N/A	$4.17 per share	N/A
GERN Geron	$183.88M	5.31	N/A	N/A	$0.34 per share	4.47
GNFT GENFIT	$41.52M	5.84	$0.07 per share	69.34	$1.50 per share	3.23
KURA Kura Oncology	$67.48M	15.67	N/A	N/A	$0.54 per share	22.02

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLYM Climb Bio	-$59.85M	-$0.83	N/A	N/A	N/A	N/A	-31.79%	-30.79%	11/5/2026 (Estimated)
GERN Geron	-$83.50M	-$0.11	N/A	25.33	N/A	-34.17%	-24.48%	-10.30%	11/4/2026 (Estimated)
GNFT GENFIT	$1.63M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
KURA Kura Oncology	-$278.67M	-$3.37	N/A	N/A	N/A	-384.30%	-207.18%	-45.17%	11/3/2026 (Estimated)

Latest GNFT, KURA, GERN, and CLYM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	KURA Kura Oncology	-$0.8773	-$0.77	+$0.1073	-$0.77	$20.16 million	$20.87 million
8/6/2026	Q2 2026	CLYM Climb Bio	-$0.2093	-$0.18	+$0.0293	-$0.18	N/A	N/A
8/5/2026	Q2 2026	GERN Geron	-$0.0089	-$0.02	-$0.0111	-$0.02	$55.30 million	$57.48 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLYM Climb Bio	N/A	N/A	N/A	N/A	N/A
GERN Geron	N/A	N/A	N/A	N/A	N/A
GNFT GENFIT	N/A	N/A	N/A	N/A	N/A
KURA Kura Oncology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLYM Climb Bio	N/A	31.45	31.45
GERN Geron	0.55	6.91	5.16
GNFT GENFIT	0.09	3.74	3.74
KURA Kura Oncology	0.12	4.73	4.71

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLYM Climb Bio	69.76%
GERN Geron	73.71%
GNFT GENFIT	2.24%
KURA Kura Oncology	N/A

Insider Ownership

Company	Insider Ownership
CLYM Climb Bio	2.60%
GERN Geron	1.71%
GNFT GENFIT	4.20%
KURA Kura Oncology	7.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLYM Climb Bio	9	57.44 million	55.94 million	N/A
GERN Geron	70	642.47 million	631.49 million	Optionable
GNFT GENFIT	120	50.03 million	47.92 million	Not Optionable
KURA Kura Oncology	130	88.96 million	82.20 million	Optionable

GNFT, KURA, GERN, and CLYM Headlines

Recent News About These Companies

Kura Oncology (NASDAQ:KURA) Insider Sells 31,487 Shares of Stock

August 22 at 7:36 AM | insidertrades.com

Kura Oncology, Inc. (NASDAQ:KURA) Given Average Recommendation of "Moderate Buy" by Analysts

August 22 at 2:29 AM | americanbankingnews.com

Kura Oncology, Inc. (NASDAQ:KURA) Given Consensus Recommendation of "Moderate Buy" by Analysts

August 22 at 2:28 AM | marketbeat.com

Kura Oncology (NASDAQ:KURA) Insider Sells 31,487 Shares

August 21 at 5:07 PM | marketbeat.com

Great Lakes Advisors LLC Invests $2.85 Million in Kura Oncology, Inc. $KURA

August 21 at 4:07 AM | marketbeat.com

Kura Oncology (NASDAQ:KURA) Hits New 1-Year High Following Insider Buying Activity

August 20 at 1:20 AM | americanbankingnews.com

Kura Oncology (KURA) Q2 2026 Earnings Call Transcript

August 19, 2026 | finance.yahoo.com

Kura Oncology (NASDAQ:KURA) Gains Traction With Its AML Menin Inhibitor

August 19, 2026 | kalkinemedia.comK

Kura Oncology (KURA) is a Great Momentum Stock: Should You Buy?

August 19, 2026 | zacks.com

Why is KURA stock rallying 8% after-hours?

August 18, 2026 | msn.com

Does Kura Oncology (KURA) Have the Potential to Rally 178.55% as Wall Street Analysts Expect?

August 18, 2026 | zacks.com

Kura Oncology (NASDAQ:KURA) Hits New 52-Week High Following Insider Buying Activity

August 18, 2026 | marketbeat.com

Why Kura Oncology (KURA) Is Up 14.5% After New Ziftomenib Resistance Data And Q2 Results

August 18, 2026 | finance.yahoo.com

Kura Oncology (NASDAQ:KURA) CEO Troy Edward Wilson Buys 100,000 Shares of Stock

August 18, 2026 | insidertrades.com

Troy Edward Wilson Purchases 100,000 Shares of Kura Oncology (NASDAQ:KURA) Stock

August 17, 2026 | marketbeat.com

Kura Oncology Q3 EPS Increased by Brookline Capital Markets

August 17, 2026 | marketbeat.com

Q3 EPS Estimates for Kura Oncology Boosted by HC Wainwright

August 17, 2026 | marketbeat.com

FY2029 EPS Estimates for Kura Oncology Decreased by Analyst

August 16, 2026 | americanbankingnews.com

Kura Oncology (NASDAQ:KURA) Stock Price Up 8% After Analyst Upgrade

August 16, 2026 | americanbankingnews.com

Kura Oncology (KURA) Receives a Buy from Bank of America Securities

August 15, 2026 | theglobeandmail.com

Kura Oncology (NASDAQ:KURA) Stock Price Expected to Rise, Wedbush Analyst Says

August 15, 2026 | americanbankingnews.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNFT, KURA, GERN, and CLYM Company Descriptions

Climb Bio NASDAQ:CLYM

$17.28 +0.26 (+1.53%)

As of 08/21/2026 04:00 PM Eastern

Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.

Geron NASDAQ:GERN

$1.52 -0.03 (-1.94%)

As of 08/21/2026 04:00 PM Eastern

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

GENFIT NASDAQ:GNFT

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.

Kura Oncology NASDAQ:KURA

$11.89 +0.18 (+1.54%)

As of 08/21/2026 04:00 PM Eastern

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GNFT, KURA, GERN, and CLYM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GNFT, KURA, GERN, and CLYM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GNFT, KURA, GERN, and CLYM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNFT, KURA, GERN, and CLYM Company Descriptions

Climb Bio NASDAQ:CLYM

Geron NASDAQ:GERN

GENFIT NASDAQ:GNFT

Kura Oncology NASDAQ:KURA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GNFT, KURA, GERN, and CLYM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GNFT, KURA, GERN, and CLYM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GNFT, KURA, GERN, and CLYM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNFT, KURA, GERN, and CLYM Company Descriptions

Climb Bio NASDAQ:CLYM

Geron NASDAQ:GERN

GENFIT NASDAQ:GNFT

Kura Oncology NASDAQ:KURA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools